Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in North Carolina: - Durham VA Medical Center — Durham, North Carolina
- CarolinaEast Medical Center — New Bern, North Carolina
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in North Carolina: - Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health University City/LCI-University — Charlotte, North Carolina
- Levine Cancer Institute-Ballantyne — Charlotte, North Carolina
- Wake Forest University at Clemmons — Clemmons, North Carolina
- Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in North Carolina: - ECU Health Oncology Kenansville — Kenansville, North Carolina
- ECU Health Oncology Kinston — Kinston, North Carolina
- ECU Health Oncology Richlands — Richlands, North Carolina
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Mission Hospital — Asheville, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
- Atrium Health University City/LCI-University — Charlotte, North Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in North Carolina: - Durham VA Medical Center — Durham, North Carolina
- Duke University Medical Center — Durham, North Carolina
- FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in North Carolina: - Duke Cancer Center Cary — Cary, North Carolina
- Duke University Medical Center (location of scans) — Durham, North Carolina
- Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
- Duke University Medical Center - Duke University Hospital (location of scans) — Durham, North Carolina
- Duke University — Durham, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 3 Recruiting Academic/Other
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…
Sponsor: University of Rochester
NCT ID: NCT05838716
Sites in North Carolina: - CarolinaEast Medical Center — New Bern, North Carolina
- Nash UNC HealthCare — Rocky Mount, North Carolina
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in North Carolina: - Durham VA Medical Center, Durham, NC — Durham, North Carolina
Phase 3 Recruiting Industry
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamid…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT07723248
Sites in North Carolina: - Urology Specialists of the Carolinas - University Place — Charlotte, North Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in North Carolina: - Durham VA Medical Center, Durham, NC — Durham, North Carolina
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC — Salisbury, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a m…
Sponsor: Phanes Therapeutics
NCT ID: NCT05652686
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Industry
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine us…
Sponsor: Monte Rosa Therapeutics, Inc
NCT ID: NCT07745361
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
Phase 2 Recruiting Industry
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…
Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in North Carolina: - W.G. Bill Hefner Medical Center — Salisbury, North Carolina
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant pr…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06457919
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive meta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07206056
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07190300
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Industry
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
Sponsor: Syntrix Biosystems, Inc.
NCT ID: NCT06228053
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will r…
Sponsor: Stephen Freedland
NCT ID: NCT05832086
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Investigators believe omeprazole may help the other medications…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT04337580
Sites in North Carolina: - W.G. Bill Hefner VA Medical Center — Salisbury, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in North Carolina: - Exelixis Clinical Site #12 — Durham, North Carolina